Dr. Tarek El Mansy is a biotech growth architect focused on Saudi Arabia and the wider MENA region, with more than twenty five years of experience across pharmaceuticals, biologics, biosimilars, vaccines, blood products, orphan drugs, medical devices, and OTC. He has built GCC and MENA businesses end to end, establishing entities, securing regulatory approvals, winning tenders, and localizing manufacturing, operating at the intersection of policy, capital, and science in alignment with Saudi Arabia’s procurement incentives, local content policies, and regional headquarters programs. His work consistently prioritizes assets addressing real unmet medical needs, compressing time to registration, engineering favourable NUPCO economics, and embedding technology transfer to ensure long term commercial resilience and national healthcare sovereignty.
He is recognised for originating, vetting, and landing high value biotech opportunities from Phase I and II through registration, pricing, reimbursement, and commercialization, and for accelerating localization so regulatory approvals convert into sustainable market share. His expertise in SFDA pathways, pricing files, and NUPCO tender dynamics enables him to translate regulatory and market access processes into measurable commercial outcomes rather than theoretical frameworks. His operating style combines deal making with financial discipline, ensuring that ventures are built as profitable, accountable businesses rather than symbolic partnerships.
Across his career, Dr. El Mansy has delivered a series of material commercial results across the region. He scaled GCC government sales from approximately eight hundred thousand dollars to around eighteen million dollars in three years while increasing margins from roughly twenty to twenty five percent to approximately eighty percent at Pharmascience. At Abdi Ibrahim he established fully foreign owned Saudi operations, designed joint venture roadmaps, and initiated a localisation funnel of around thirty assets. At Accumedica he delivered approximately eight million dollars in cumulative shortage and non registered tender wins across Saudi Arabia, the UAE, Bahrain, and Kuwait. At DDC he designed a fifteen asset biosimilars localisation plan structured around joint venture economics targeting more than two hundred million dollars in Saudi tender revenue. At Ivax he tripled MENA revenue from approximately ten million euros to thirty million euros within thirty six months while expanding distribution from eight to eighteen markets and resolving chronic supply constraints.
His functional expertise spans biologics and biosimilars, vaccines, cell and blood products from a commercialisation perspective, rare and specialty medicines, hospital, ICU, and oncology portfolios, market access across SFDA, NUPCO, MOHAP, and DHA, pricing, health technology assessment and contracting, portfolio and evidence strategy, joint venture and technology transfer structures, regulatory and pharmacovigilance governance, distributor strategy and channel economics, sales and operations planning, supply security, IPO readiness, and board level reporting. He consistently applies this breadth of capability to build integrated commercial and regulatory strategies that align clinical development, payer evidence, pricing, and access to accelerate time to revenue.
In advisory and engagement roles, he has supported Aquilon Pharma in Belgium by building a GCC equity thesis of twenty million euros for its inhaled platform and mapping manufacturing partners for accelerated scale up. He has worked with Euromonitor International to support a Saudi pharmaceutical client’s IPO readiness and market narrative for a transaction exceeding three hundred million dollars. He has guided Oxypoint NV through GCC registration and distributor development for its patented oxygen flow meters, creating a launch path and hospital access strategy. He has also repeatedly engaged with SFDA, NUPCO, MOHAP, and DHA, converting policy frameworks into executable commercial outcomes.
Dr. El Mansy operates with a governance philosophy built around board grade transparency, disciplined prioritisation, and clean execution. He insists on audit ready documentation, clear decision logs, and KPI frameworks that link scientific milestones directly to commercial performance, and he fosters a culture that is candid, metrics driven, and respectful, built on high trust and zero tolerance for underperformance. He holds a Bachelor of Science in Pharmaceutical Sciences in Clinical Pharmacy from King Saud University in Riyadh and an Advanced Diploma in Integrated Sales and Marketing from the Riyadh Chamber of Commerce. He is a native Arabic speaker, fluent in English, and has a working knowledge of French.
